Overview

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine (ara-C). In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.

Phase:

Phase 2

Details

Lead Sponsor:

Clavis Pharma

Collaborators:

INC Research
Syneos Health
Theradex

Treatments:

Cytarabine
Idarubicin